PF-Atlas › Treatments › ROCK Inhibitor — Inhaled Fasudil
ROCK Inhibitor — Inhaled Fasudil
Reduces cytoskeletal tension, reverses myofibroblast — breaks ECM stiffness loop
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase II
Evidence level
Level 2 (Phase II Japan)
Mechanism class
Reduces cytoskeletal tension, reverses myofibroblast — breaks ECM stiffness loop
Timeline
2-4 years
Risk profile
Low-Medium
Developer
Multiple (Japan)
Key researchers
K. Kuwano
Overview
Fasudil approved in Japan for other uses. Inhaled formulation reduces systemic BP effects. Softens fibrotic matrix.
How ROCK Inhibitor — Inhaled Fasudil fits into IPF treatment
ROCK Inhibitor — Inhaled Fasudil is classified as Level 2 (Phase II Japan) at the Phase II stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about ROCK Inhibitor — Inhaled Fasudil for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.